EPG Online Twitter
EPG Online Blog
Disease Knowledge
Drug Updates
- Enbrel 25 mg powder and solvent for solution for injection
- Sustiva 50 mg, 100 mg and 200 mg Hard Capsules
- Sandostatin LAR
- Difflam Oral Rinse
- Teoptic 1% - Teoptic 2%
- Erythroped A 500 mg Tablets
- Enalapril 5mg Tablets
- Viskaldix Tablets
- Aricept Tablets
- Difflam Cream
- Alfentanil 500 micrograms/ml solution for injection
- Revlimid
- Benadryl Plus Capsules
- Diclomax Retard
- Voltarol Tablets
- Virgan
- DIXARIT (menopausal disorders)
- Rapiscan (regadenoson)
- Neurontin Capsules and Tablets
- Aprovel Film-Coated Tablets (sanofi-aventis Bristol-Myers Squibb SNC)
- Foradil
- Nystatin-Dome Suspension 100,000 I.U./ml
- Meningitec in pre-filled syringe
- Catapres Tablets 100mcg
- Kemadrin 5 mg Tablets
- SECTRAL 400mg tablets
- Sectral 100mg and 200mg
- Eucardic 25mg Tablets
- ALDOMET Tablets 250 mg
- Parvolex 200 mg/ml Concentrate for Solution for Infusion
- Mifegyne
- Pedea 5 mg/ml solution for injection
- Eucardic 12.5mg Tablets
- Qvar 100 Easi-Breathe
- Qvar 50 Easi-Breathe
- Eucardic 6.25mg Tablets
- Qvar MDI 50 micrograms
- Sonata 5 mg hard capsules
- PRO-EPANUTIN
- Xarelto 20mg film-coated tablets
Disease Knowledge Centres feed
Working with our pharmaceutical industry partners we have compiled the EPG educational library. The library contains interactive educational resources from specific drug treatments through to more general disease and management guides. The content is classified by therapeutic area and can be accessed by clicking the links below.
In order to access the following content you must be a qualified physician or other medical professional, by clicking any of the links within the educational library you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Alzheimer's disease (AD) is a progressive, neurodegenerative disease which will affect most of us at one point in time - either directly (as the prevalence is expected to quadruple over the next 50 years) or indirectly through the suffering of a loved one.
What’s in the Alzheimers Knowledge Centre?
- Prevalence of Alzheimers
- Symptoms of Alzheimers
- The stages Of Alzheimers
- Types of Dementia
- Disease Progression
- Treatment Options
- Cholinesterae Inhibitors
- NMDA Receptors Antagonists
- Pipeline Treatments
- Downloads
- Clinical Studies
- Useful Links
- Patient Resources
- Tips for Caregivers
- Downloads for Patients
- What the Experts Say
- Active Ingredient & MoA
- Indication & Diagnosis
- Dosage Application
- Evaluating Success
- Side Effects & Interactions
- Prescription & Costs
Arthritis is a complex disorder that comprises more than 100 distinct musculoskeletal conditions and can affect people at any stage of life. Arthritis causes joint pain, loss of movement, and inflammation. Common forms of arthritis include osteoarthritis (OA) and rheumatoid arthritis. Both OA and RA are chronic and incurable but respond well to intervention..
What’s in the Arthritis Knowledge Centre?
- Osteoarthritis (OA)
- Rheumatoid Arthritis
- Inflammatory Arthritis
- Diagnosis
- Pain Assessment
- Pain Management
- Children and Older Adults
- Treatment options
- Non-Pharmacological Treatment
- Pharmacological
- Complementry Therapy
- Surgery
- Resources: Physicians
- Resources: Patients
Asthma is a disorder defined by its clinical, physiological, and pathological characteristics. The main physiological feature of asthma is episodic airway obstruction characterized by expiratory airflow limitation. The dominant pathological feature is airway inflammation, sometimes associated with airway structural changes..
What’s in the Asthma Knowledge Centre?
- Burden of Disease
- Causes of asthma
- Definition of Asthma
- Development & Progression of Asthma in adolescents and children
- Asthma Home
- Inflammation in the peripheral airways
- Pathophysiology - Asthmatic Inflammation
- Pathophysiology of asthma
- The asthmatic response
- Worldwide Prevalence
- Classification
- Diagnosis
- Education
- Levels of asthma control
- Management
- Measurement of airway responsiveness
- Measurements of Lung Function
- Peak expiratory flow measurements
- Risk Factors
- Signs & Symptoms
- Spirometry tests
- Resources -Weblinks
- Alvesco - Summary of Product Characteristics (SPC)
- Alvesco
- Clinical efficacy
- Corticosteroids
- Management using the stepwise approach
- Monitoring to maintain control
- Pharmacodynamics - Targeted deposition and activation
- Pharmacokinetics of Alvesco
- Safety and tolerability
- Treatment Options - Non-Pharmacologic
- Treatment Options - Pharmacologic
Atopic dermatitis is a highly prevalent disease in developed countries, affecting 10–30% of children and 1–3% of adults.1,2 Often referred to as ‘eczema’, atopic dermatitis is a chronic inflammatory skin disorder.
What’s in the Atopic Dermatitis Knowledge Centre?
- Areas of the body commonly affected by atopic dermatitis
- Assessment
- Diagnosis
- Education
- Non-pharmacological therapy
- Pharmacological therapy
- General Management
- Overview
- Signs and symptoms of atopic dermatitis
- Glossary
- References
- Resources - Websites and Materials
- Non-pharmacological treatments
- Treatment Overview
- Focus on LOCOID
- Focus on PROTOPIC
- Topical calcineurin inhibitors
- Pharmacological treatment - Topical corticosteroids
- Phototherapy
- PROTOPIC - Efficacy and Safety
- PROTOPIC - Frequently asked questions, Topical calcineurin inhibitors
- PROTOPIC - Mode of Action
- Treatment Summary
- Treatment Adjuncts
- Burden
- Causes
- Definition
- Environmental factors
- Genetic factors
- Immune system dysfunction
- Skin barrier function
- Pathophysiology
- Prevalence
An elevated level of low-density lipoprotein cholesterol (LDL-C) is a form of dyslipidaemia that has been shown to be strongly associated with an increased risk of developing atherosclerosis and cardiovascular disease (CVD), leading to cardiovascular events.
What’s in the Cholesterol Knowledge Centre?
- Home
- Lipids
- Lipoproteins
- Cholesterol
- Dyslipidaemia
- Atherosclerosis
- Cardiovascular disease
- Cardiovascular risk factors
- Risk assessment
- LDL-cholesterol
- Additional risk factors
- Screening
- European guidelines
- NCEP guidelines
- Cardiovascular risk management
- Treatment options
- Additional medical treatments
- Diet & exercise
- Monitoring therapy
- References
Throughout life, the bone marrow continuously produces a variety of blood cell lineages in a tightly controlled, yet flexible process termed haematopoiesis1. The 2 main groups of mature blood cells are red blood cells (RBCs) and white blood cells (WBCs), or leukocytes...
What’s in the CML Knowledge Centre?
- CML Home
- CML Management - Diagnosis
- Current Treatment Options
- ELN Recommendations
- Historical Perspective - Chemotherapy
- Historical Perspective - Interferon Alfa
- Historical Perspective - Stem-Cell Transplantation
- Ongoing Management
- Other Therapeutic Approaches
- Prognosis - Goals of Therapy
- Prognosis
- Treatment - historical perspective
- Resources - Imatinib
- Resources - Nilotinib
- Useful Links (General)
- Efficacy: Phase I
- Efficacy: Phase II
- Imatinib - Clinical Efficacy
- Imatinib - Glivec
- Imatinib - Indication
- Imatinib - Mechanism of Action
- Imatinib - Rationale
- Imatinib - Safety Information
- Nilotinib- Adverse Events
- Nilotinib - Mechanism of Action
- Nilotinib- Preclinical Studies
- Nilotinib- Rationale
- Nilotinib - Response Criteria
- Nilotinib- Safety information
- Nilotinib - Tasigna
- Clinical Presentation
- Epidemiology
- Haematological Malignancy and Leukaemia
- Pathophysiology
- Phases of Disease
- Understanding CML - Haematopoiesis
The Contraception Knowledge Centre provides help and guidance to assist physicians in selecting the most appropriate contraceptive method for their patient.
What’s in the Contraception Knowledge Centre?
- NICE Guidelines
- WHO Guidelines
- Contraception Home Page
- Making The Choice
- Calendar Wheels
- Organisations/Associations
- Patient Leaflets
- Emergency Contraception
- Contraception and bone health
- Hormonal Methods - Daily
- Hormonal Methods - LARCs
- Hormonal Methods - Monthly
- Hormonal Methods - Weekly
- Hormonal Methods
- Male Contraception
- Non-Hormonal Methods - Barriers
- Non-Hormonal Methods - IUD
- Non-Hormonal Methods - Surgery
- Non-Hormonal Methods - Traditional Methods
- Non-Hormonal Methods
- Oral contraception is used daily
- E-leave Piece for GP's
- Case Study - Focal Migraine
- KOL - Webcast
- Case Study - LARC
- Case Study - WHO Guidance
- Case Study
Patients with Cystic Fibrosis (CF) develop a wide range of clinical consequences and experience varying degrees of disease severity. Regardless of its clinical presentation, the basic problem of the disease is the same – an abnormality in the glands that produce or secrete sweat and mucus.
What’s in the Cystic Fibrosis Knowledge Centre?
- Definition
- Causes of Cystic Fibrosis (CF)
- Physiologic Consequences
- Incidence and Prevalence
- Clinical Consequences
- Effects on the Respiratory System
- Effects on the Digestive system
- CF- related Diabetes Mellitus
- Effects on the Heart
- Other Effects of Cystic Fibrosis
- Early screening and Diagnosis
- Clinical Manifestation
- Multiple Organ Involvement
- Progression of Respiratory Clinical Features
- Complications of Lung Disease
- Other Symptoms Affected by CF
- Diagnostic Approach
- Lung Function Tests
- Spirometry Testing
- Pulmonary Function Tests
- Management of Cystic Fibrosis
- Nutritional Support
- Lung Management
- Management of the Digestive System
- Management of the Gallbladder and Liver
- Management of the Pancreas
- Prognosis
- Antibiotic Therapy
- Emerging Pathogens
- Anti-inflammatory Therapy
- Severe Disease
- Resources - FAQ
The prognosis of patients with diabetes is improved by interventions that reduce HbA1C which is influenced by both fasting and postprandial blood glucose levels. Postprandial hyperglycaemia per se is also an independent risk factor for adverse cardiovascular outcomes and complications of diabetes.
What’s in the Diabetes Knowledge Centre?
- Screening & Diagnosis
- Lifestyle management
- Oral Agents
- Insulin Therapy
- Dual Action
- Short Term Action
- Product benefits
- References
- Suitable Devices
- In pump therapy
- The Need For Insulin Analogues
- Rationale
- IDF 2005
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract. Before the current definition of GIST evolved, GISTs were classified as benign or malignant smooth muscle tumours including true smooth muscle tumours (leiomyomas, leiomyoblastomas, leiomyosarcomas) and neuronal tumours (schwannomas)
What’s in the GIST Knowledge Centre?
- GIST Home
- Current Options
- Diagnosis- Histopathology
- Diagnosis- Immunohistochemistry
- Diagnosis
- Differential Diagnosis
- Goals of therapy
- Historical perspective
- Ongoing Management
- Other Therapeutic Approaches
- Prognosis
- Treatment Guidelines
- GIST Molecular Target animation
- Resources
- Useful Links
- Imatinib - Clinical Investigation
- Imatinib - Efficacy
- Imatinib - Management of Adverse Events
- Imatinib - Mechanism of Action
- Imatinib - Monitoring
- Imatinib - Progression
- Imatinib - Rationale
- Imatinib - Resistance
- Imatinib - Safety and Tolerability
- Definition
- Epidemiology
- Etiology
- Pathophysiology
- Symptoms
Hepatitis can be caused by many different things including viral infections, parasites, bacteria, chemicals, autoimmunity, drugs or alcohol. Of these, viral infection is the most common cause of chronic (long-term) hepatitis, which can lead to severe liver damage including cirrhosis and liver cancer.
What’s in the Hepatitis Knowledge Centre?
- Home
- Hepatitis B: Prevalence
- Hepatitis B: Burden
- Symptoms and Sequelae of Chronic Infection
- Hepatitis B: Modes of Transmission
- Hepatitis B: Viral Features
- Hepatitis B: Genotypes
- Hepatitis B:Natural history
- Hepatitis B: HBeAg status
- Hepatitis C: Prevalence
- Hepatitis C Virus Genotypes
- Hepatits C: Natural history
- Hepatitis C: Symptoms
- Transmission of Hepatitis C Virus
- Hepatitis C: High Risk Groups
- Stigma of Hepatitis C
- Hepatitis C: Screening
- Hepatitis C: Diagnosis
- Long-Term Consequences of Hepatitis C
- Quality of Life
- Overview
- Hepatitis C: Pegylated interferon alfa combined with Ribavirin
- Hepatitis C: Pharmacology
- Hepatitis C: Efficacy
- Hepatitis C: Emerging Therapies
- Side Effects for Hepatitis C
- Hepatitis C: Therapy Goals
- Patient-specific Treatment Consideration for Hepatitis C
- Special Patient Groups
- Diagnostic Tests & Patient Monitoring
- Hepatitis C:Treatment Guidelines
- Aetiology
- Glossary
Worldwide, every two minutes a woman dies of cervical cancer. Globally, cancer of the cervix is the second most prevalent cancer in women, causing nearly 500,000 new cases per year, and the third leading cause of female cancer deaths after breast and lung cancer. Each year an estimated 270,000 women die from the disease, 85% of whom are from the developing world.
What’s in the HPV & Cervical Cancer Knowledge Centre?
- Overview
- Human papillomavirus (HPV)
- Natural History of HPV
- HPV Transmission and Acquisition
- Cervical Cancer Risk Factors
- From Oncogenic HPV to Cervical Cancer
- Immunology of HPV Infection
- Virology
- The Character of HPV
- HPV and Cervical cancer
- Other Disease Caused by HPV
- Epidemiology
- Geography
- Cervical Cancer and Age
- Lifetime Risk of Cervical Cancer
- The Cervix
- Anatomy
- Cell Biology
- Immunology of the Cervix
- Impact of abnormal screening results, pre-cancerous lesions and cervical cancer
- Impact of abnormal screening results, pre-cancerous lesions and cervical cancer on quality of life (QoL)
- Impact of Cervical Cancer on Years of Life Lost (YLL)
- Societal costs of pre-cancerous lesions and Cervical Cancer
- Prevention & Treatment of oncogenic HPV and cervical cancer
- Screening for Cervical Cancer
- Impact of Abnormal Screening Results
- Treatment of CIN and Cervical Cancer
- Prevention of Cervical Cancer where screening not implemented
- Frequently Asked Questions
- References
Hypertension, an increasingly common and chronic disease, and its consequences like stroke, coronary heart disease, heart failure and renal damage mean an enormous financial burden for the community.
What’s in the Hypertension Knowledge Centre?
- Home
- Definition/Classification hypertension
- Diagnostic Evaluation
- Cardiovascular Disease Risk Factors
- The importance of Systolic Hypertension
- Hypertension and the Metabolic Syndrome
- Initiating Treatment
- Lifestyle Interventions
- Pharmacological Interventions
- Role played by angiotensin II and the sympathetic nervous system in determining systolic blood pressure
- Role played by angiotensin II
- Primary intervention studies using AIIAs
- A Dual Mechanism of Action
- Overview of efficacy with eprosartan in essential hypertension
- Eprosartan - effect on systolic blood pressure and pulse pressure
- Other Efficacy Trials
- Eprosartan in the secondary prevention of stroke: the MOSES study
- Effect of eprosartan on blood platelets and fibrinolytic function
- Renoprotection: the role of eprosartan
- Tolerability and safety of eprosartan
- Chemistry and pharmacokinetics of eprosartan
- Dosage and administration of eprosartan
- Summary: Benefits of eprosartan for patients with high blood pressure
- References for Eprosartan
- References for Moxonidine
- Overview of moxonidine
- Monotherapy - Efficacy of moxonidine versus active comparators
- Dose-response of moxonidine
- Long-term efficacy
- Role of moxonidine in combination with other antihypertensives
- Moxonidine in postmenopausal hypertensive women
- Moxonidine in hypertensive patients with left ventricular hypertrophy
- Renal protection: the role of moxonidine
- Tolerability and safety of moxonidine
- Chemistry and mode of action of moxonidine
- The Effects of Moxonidine
- Pharmacokinetics of moxonidine
- Dosage and administration of moxonidine
- Therapeutic Approach in Special Conditions
- Resources
Insomnia is a very common and debilitating disease with major morbidity and social consequences. Despite the negative impact on the ability to function well during the day, insomnia is underdiagnosed and undertreated.
What’s in the Insomnia Knowledge Centre?
- Characterisation of Insomnia
- Classification
- Insomnia
- Diagnosis
- Impact of Insomia
- Insomnia Home
- Prevalence
- Types
- Abbreviations
- Journal Abstracts
- Useful downloads
- Useful Web Links
- Antidepressants
- Benzodiazepine Receptor Agonists
- Treatment Options
- Non-prescription (OTC) Medications
- Assessment Tools
- Circadin
- Melatonin Receptor Agonists
- Leeds Sleep Evaluation Questionnaire
- LSEQ versus PSQI
- Pittsburgh Sleep Questionnaire
- Sleep Diaries
- WHO-5 Well-being Index
- Non- Pharmacological: Alternative therapies
- Non- Pharmacological: Cognitive therapy
- Non- Pharmacological
- Non- Pharmacological: Sleep Hygiene Education
- Circadian Rhythms: Sleep–wake cycle
- Circadian Rhythms
- Function of Sleep
- Melatonin
- Monitoring Sleep
- Neurobiology of Sleep
- Sleep Architecture: Sleep cycle stages
- Sleep Architecture
Lysosomal storage disorders (LSDs) are a group of progressive and often fatal genetic diseases that are caused by an inborn error of metabolism.
What’s in the Lysosomal storage disorders (LSDs) Knowledge Centre?
- About Lysosomal Storage Disorders
- When to suspect
- Alerting symptoms
- Mucopolysaccharidosis Type I (MPS I)
- Gaucher disease
- Fabry disease
- Pompe disease
- Diagnosis
- Diagnostic tests for lysosomal storage disorders
- Treatment options for MPS I, Gaucher, Fabry and Pompe disease
- Learn more about lysosomal storage disorders: Disease Information
- Learn more about lysosomal storage disorders: Treatment Information
- List of relevant literature
This resource is aimed at physicians who are involved in the diagnosis, treatment and monitoring of men with hypogonadism. It aims to provide a better understanding of the epidemiology and etiology of male hypogonadism, the diagnostic procedures and the available treatment options for hypogonadal men.
What’s in the Men's Health Knowledge Centre?
- Congresses
- home
- Men's health
- Definition
- Prevalence
- Symptoms
- Clinical examination
- Laboratory testing
- Patient based
- Physical examination
- Specialized diagnostic tests
- How erection works
- Problems with erection
- Lifestyle
- Medication
- Metabolic Syndrome
- Overview
- Prostatectomy
- Testosterone Deficiency and Hypogonadism
- Algorithm
- First- line therapy
- Second-line therapy
- Third-line therapy
- Duration
- ED & Diabetes
- ED & Dyslipidemia
- ED & Hypertension
- ED & metabolic syndrome
- ED & Radical Prostatectomy
- ED & The Role of Female Partner
- Fast onset
- First dose Success
- Hardness
- Mode of Action
- PERT
- Pharmacokinetics
- Pharmacology
- Receptor Affinity
- Reliability
- Safety & Tolerability
- Diagnosis - Diagnosis and Treatment Algorithm
- Diagnosis - Symptoms, Physical Examination, Blood Tests
- Etiology - Etiology Of Hypogonadism
- Etiology - Late Onset Hypogonadism
- Etiology - Primary and Secondary Hyponadism
- Etiology - Risk Factors For Hypogonadism
- Overview - Current treatment and controversies
- Overview - How are men affected by hypogonadism?
- Overview - How important is it to treat hypogonadism
- Overview - Hypogonadism Defined
- Overview - Hypogonadism Prevalence
- Diagnosis - Symptoms, Physical Examination, Blood Tests
- Treatment Options - Safety Of Testosterone Replacement Therapy
- Treatment Options - What Are The Benefits Of Treating Hypogonadism?
- Treatment Options - What Treatments Are Available?
- Treatment Options
- Latest Updates
- Testogel reduces fat and improves body
- Testosterone improves functional performance
- Testosterone reduces visceral fat
- Associations & Organisations
- Further Reading - Erectile Dysfunction
- Further Reading - Hypogonadism
Migraine is a common neurological disorder characterised by recurrent episodes of headache pain with associated symptoms including nausea, vomiting, sensitivity to light and sound, and, in a minority of patients, transient neurological symptoms, with visual disturbances being the most common.
What’s in the Migraine Knowledge Centre?
- Home
- Is it Migraine?
- Migraine: Quick Check
- Migraine without aura: International Headache Society classification
- Migraine with typical aura: International Headache Society classification
- Headache
- Primary headache
- Secondary headache
- Migraine Aetiology
- What is Migraine?
- What Causes Migraine?
- Migraine triggers
- Migraine Epidemiology
- Economic Impact of Migraine
- Treating Migraine
- Screening
- Diagnosis
- Migraine Treatment Guidelines
- Headache Care for Practising Physicians (HCPC)
- US Headache Consortium Guidelines
- Migraine Treatment Options
- Acute Migraine Treatments
- Triptans
- Other acute migraine treatments
- Preventative Migraine Treatments
- Non-Pharmacological Migraine Treatments
- Migraine Treatment Strategies
- Step Care Across Attacks
- Step Care Within Attacks
- Stratified Care
- Zomig
- Zomig Nasal Spray
- 'Zomig Rapimelt'
- 'Zomig' Classic Tablets
- Zomig full prescribing information
- Migraine Disability Assessment (MIDAS) Questionnaire
- Patient Diary
- Managing Your Migraine Booklet
- Migraine & Headache Resources
The hallmark of multiple sclerosis (MS) as revealed by magnetic resonance imaging (MRI) is the white matter plaque, which represents an area of demyelination and axonal loss. MS can produce lesions throughout the central nervous system (CNS).
What’s in the Multiple Sclerosis Expert Centre?
- Home
- Background
- Pathogenesis
- Epidemiology
- Diagnosis
- Treatment
- Conferences and Congresses
- Recommended reading
Niemann-Pick type C disease is a rare genetic lysosomal storage disorder that causes severe, progressive neurological symptoms. It is a very serious, life-threatening condition that can affect infants, children and adults. NP-C is characterized by cellular accumulation of lipids, in particular unesterified cholesterol and glycosphingolipids, in many parts of the body including brain, liver and spleen.
What’s in the Niemann-Pick Knowledge Centre?
- Epidemiology
- Impact of NPC
- Home
- Prognosis
- Signs and symptoms
- Introduction
- Diagnostic Testing
- Initial Evaluations
- Misdiagnosis
- Specialist Referral
- Carrier Detection and Genetic Counselling
- Genetics of NPC
- Mutations
- Patterns of inheritance
- Neuropathology
- NPC Defects in Lipid Trafficking
- Roles of NPC gene products in pathogenesis
- Glossary
- Resources - External Links
- Evaluating clinical treatment effects
- Specific Therapies
- Symptomatic Therapies
The NSCLC's account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]).
What’s in the Non-small Cell Lung Cancer Knowledge Centre?
- Home
- Non-small Cell Lung Cancer
- Causes
- Risk Factors
- Histology/Pathology
- Disease Staging/Prognosis
- TNM Systems
- Factors that affect prognosis
- Signs and Symptoms
- Diagnosis
- Early Stage disease (stage I, II, IIIA)
- Treatment Strategies
- Advanced disease (stage IV)
- Quality of Life in advanced NSCLC
- Future Strategies
- Treatment Therapies
- Chemotherapy
- First-line Therapy
- Second-line Therapy
- Unmet clinical need in advanced NSCLC
- Targeted therapies - Overview of cytotoxic drugs
- Recent developments in Cancer Cell Biology
- Current therapy - Erlotinib
- Resources
- Downloads - Physicians Materials
- Patient
- Downloads - Patient support
Age-related macular degeneration (AMD) is the most common cause of legal blindness among people over the age of 50 in the Western world. It affects the macula, the central part of the retina. As the photoreceptors begin to deteriorate, so does the central vision needed for everyday activities such as reading or driving.
What’s in the Ophthalmics Knowledge Centre?
- Age-Related Macular Degeneration
- Choroidal neovascularization
- Clinical development
- Efficacy
- Safety
- Pharmacokinetics
- Pharmacodynamics
- Administration and light application
- Patient information
- References
- Chronic Eye Discomfort
- Allergic Irritation
- Allergen Challenge Studies Versus Placebo
- Studies with Active Controls
- Nasal Effects/Adjuntive or Combined Therapy
- Quality of Life
- Safety
- Product Summary
- Delaying Progression
- Lutein
- The Age-Related Eye Disease Study (AREDS)
- Clinical Reports
- Physician downloads
- Patient Resources
Opioid analgesics are used to relieve moderate to severe pain. They can be used in the acute setting and are also appropriate for the treatment of certain cases of persistent non-cancer pain.
What’s in the Opioids and Pain Knowledge Centre?
- Opioids and Pain Home
- Effects
- Pain Measurement
- Prevalence of chronic pain
- Types of chronic pain
- Administration
- Adverse effects
- Classification
- Cognitive impairment
- History
- Opioids
- Misconceptions
- Opioid interactions with concomitant medications and their effects on concomitant disease
- Opioid use at different ages
- Opioid use in patients with drug abuse
- Prescription drug abuse
- Strong Opioids
- Use in palliative care
- Why Opioids?
- Additional and Complementary Therapy
- Initiating Therapy
- Medication
- Monitoring
- Downloads
- Resources
- Multimedia
- Oxy Case Studies - Cancer Pain
- Oxy Case Studies - Post Op
- Oxycontin/OxyNorm Case Studies
- Palladone Case Studies 5-8
- Palladone Case Studies - Renal
- Palladone Case Studies
- PIL Table
- Transtec Case Studies
- Weblinks
Osteoporosis is a condition where the bones become thin and weak, and break easily. Osteoporosis frequently goes undiagnosed until such a fracture occurs; with a condition like this there are no warning signs. Areas particularly vulnerable are the spine, wrist and hips.
Parkinson’s disease (PD) is a progressive, degenerative disorder of the central nervous system, which causes increasing disability over time. PD predominantly occurs in people over the age of 50 and is the commonest neurodegenerative disorder after Alzheimer’s disease that a physician will encounter.
What’s in the Parkinson's Knowledge Centre?
- Parkinsons Disease Home
- Assessing Parkinson's disease severity
- Epidemiology
- Guidelines for diagnosing Parkinson's disease
- Making a diagnosis of Parkinson's disease
- Pathophysiology
- Amantadine
- Catechol-O-methyltransferase inhibitors
- Conventional levodopa
- Dopamine agonists
- Established/advanced Parkinson's disease
- Levodopa infusion
- Limitations with conventional levodopa therapy
- Making therapy choices (based on EFNS guidelines) - Early Parkinson's Disease
- Mode of action of anti-parkinsonian therapy
- Modification strategies for conventional levodopa
- Monoamine oxidase B inhibitors
- Potential Benefits of Early Optimisation of Levodopa Therapy
- References Cited
- Summary of Stalevo an optimized levodopa therapy
- Surgical Options
- Treatment options
- Congress Calendar
- Links
- Meetings reports
- Publications
- Announcements
- Building a Parkinson's disease patient-care team
- Contacts
- Diagnostic and patient assessment tools
- Information for healthcare professionals
- LEAP download section - ABPI
- Leap Downloads - Non ABPI
- Patient communication aids
Acute coronary syndrome (ACS) is a broad term that includes the diagnoses of unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). UA and NSTEMI are sometimes referred to collectively as non-ST-segment elevation ACS (NSTE-ACS).
What’s in the Post-MI Heart Failure Knowledge Centre?
- Definitions and Epidemiology
- Aetiology and Pathophysiology
- Diagnosis
- Management
- Complications and Prognosis
- Risk Factors
- Definitions and Types of Heart Failure
- Epidemiology
- Pathophysiology
- Signs and Symptoms
- Ipmacy
- Diuretics
- Antiplatelet Agent and Anticoagulants
- Beta Blockers
- ACE Inhibitors and Angiotensin II Receptor Blockers
- Aldosterone Receptor Antagonists
- Oral Nitrates and Hydralazine
- Statins
- Digoxin
- Counselling and Education
- Lifestyle Modification
- Invasive Procedures
- Implantable Cardioverter-Defibrillators
- Monitoring
- Guidelines
- Useful Links
- Conferences and Congresses
- Multimedia
Amongst the topics covered, the Knowledge Centre includes an up-to-date summary of the epidemiology and classification, detection and management of this prevalent neoplasm, with a particular focus on hormonal therapy.
What’s in the Prostate Cancer Knowledge Centre?
- Prostate Cancer Home
- Incidence and Mortality
- Risk Factors
- Histological Classification
- Pattern of Disease Spread
- Symptoms
- Screening
- Diagnosis
- Staging
- Risk Stratification
- Management Overview
- Deffered Treatment
- Radiotherapy
- Radical Prostatectomy
- Experimental Local Therapies
- Hormonal Therapy
- LHRH agonists
- Chemotherapy
- Clinical Updates
- Physician Resources
- Patient Resources
Chronic Kidney Disease (CKD) is characterised by a gradual and permanent loss of kidney function that worsens as it progresses from stages 1 to 5. One of the most common complications of CKD is anaemia. Renal anaemia is secondary to chronic kidney disease (CKD) and it appears early in the course of CKD, worsening as it progresses.
What’s in the Renal Anaemia Knowledge Centre?
- Renal Anaemia Home
- Definition
- Epidemiology of CKD
- Incidence and Prevalence of Stage 5 CKD
- Treatment of CKD
- Renal Anaemia: Definition
- Causes
- Effects
- Challenges
- Associated Symptoms
- CKD and Anaemia
- CKD and renal Anaemia
- Implications of CKD related anaemia
- AnaemiaWorld
- Diagnosis: Overview
- Haemoglobin levels in renal anaemia
- Diagnostic flow chart
- Diagnostic tests: Establishing the cause of anaemia
- Diagnostic tests: Determining kidney function
- Diagnostic tests: Comorbidities tests
- Introduction
- Anaemia Treatment In CKD Patients
- Current Challenges in the Management of CKD-Related Anaemia
- Introducing C.E.R.A
- mode of action
- Safety
- SPC
- Clinical Study highlights
- Treatment guidelines
- Current issues in anaemia management
- Useful External Links
Kidney cancer is the 14th most common cancer and there were approximately 200,000 new kidney cancer cases worldwide in 2002. RCC is a global problem, but its incidence varies considerably by geographical location. Rates of RCC are high in North America, Europe and Australia, whereas rates are low in Africa, India and China.
What’s in the Renal Cell Carcinoma Knowledge Centre?
- Overview
- Incidence
- Prevalence
- Aeitology
- Classification
- Dignosis and Staging
- Radiological Investigations
- Renal Biopsy
- Histological Diagnosis
- Disease Staging
- Management and Treatment
- Treatment Options
- Adjuvant Therapy
- Prognostic Factors
- Treatment Guidelines
- Resources
Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.
What’s in the Soft Tissue Sarcoma Knowledge Centre?
- Feedback
- Home
- Introduction
- Staging and Risk Assessment
- Chemotherapy
- Disease Progression
- Management - Overview
- Novel Therapy - Trabectedin - Clinical Studies
- Novel Therapy - Trabectedin - Clinical Updates
- Novel Therapy - Trabectedin - Efficacy
- Novel Therapy - Trabectedin - Mode of action
- Novel Therapy - Trabectedin - Research and Advances
- Novel Therapy - Trabectedin - Safety And Tolerability
- Novel Therapy - Trabectedin
- Radiotherapy
- Surgery
- Associations and Organisations
- Congresses
- Glossary
- Guidelines
- Research Groups
- Classification
- Clinical Presentation
- Epidemiology
- Types By Site





